By Will Feuer

 

Danaher Corp. said it expects base business core sales to grow in the mid-single digit percent range for the current quarter, despite a hit from the Covid-19-related restrictions across China.

The medical and diagnostics company's base business core sales figure strips out sales related to Covid-19 testing but includes sales from products that support Covid-19-related vaccines and therapeutics.

For the full year, the company said it expects base business core sales growth to be in the high-single digit percent range.

For both the second quarter, which ends July 1, and the full year, Danaher said it expects to see a low-single digit percentage benefit to sales from Covid-19 related testing.

 

Write to Will Feuer at Will.Feuer@wsj.com

 

(END) Dow Jones Newswires

April 21, 2022 06:36 ET (10:36 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Danaher (NYSE:DHR)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Danaher Charts.
Danaher (NYSE:DHR)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Danaher Charts.